RESET-SSc: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201, a CD19-CAR T Cell Therapy, in Subjects With Systemic Sclerosis
Conditions
Systemic Sclerosis · Scleroderma
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Yale University, New Haven, Connecticut, United States
Contact: Principal Investigator (Dr. Monique Hinchcliff, MD, MS)Mayo Clinic Florida, Jacksonville, Florida, United States
Contact: Principal Investigator (Dr. Andy Abril, MD)Northwestern Memorial Hospital, Chicago, Illinois, United States
Contact: Principal Investigator (Dr. George Georges, MD)The University of Chicago Medical Center, Chicago, Illinois, United States
Contact: Principal Investigator (Dr. Michael Macklin, MD)University of Kansas Medical Center, Kansas City, Kansas, United States
Contact: Principal Investigator (Dr. Paul Schmidt, MD)University of Michigan, Ann Arbor, Michigan, United States
Contact: Principal Investigator (Monalisa Ghosh, MD)Mayo Clinic Rochester, Rochester, Minnesota, United States
Contact: Principal Investigator (Ashima Makol, MD)Columbia University Irving Medical Center, New York, New York, United States
Contact: Principal Investigator (Elana Bernstein, MD)University of Rochester, Rochester, New York, United States
Contact: Principal Investigator (Benjamin Korman, M.D.)Duke University, Durham, North Carolina, United States
Contact: Principal Investigator (Ankoor Shah, MD)
Study leads
Medical Director
Study Director
Cabaletta Bio